Hypoxic antiblastic stop-flow perfusion: Clinical outcome and pharmacokinetic findings

Pierluigi Pilati, D. Miotto, S. Bertolo, M. Minante, T. Darisi, S. Mocellin, D. Casara, C. Ori, M. Foletto, C. R. Rossi, M. Lise, D. Nitti

Research output: Contribution to journalArticlepeer-review


Stop-flow perfusion (SFP) is a recently implemented locoregional treatment based on the vascular isolation of the tumor bearing body district through a radiointerventistic technique. SFP is currently under investigation as a palliative therapeutic option for patients with locally advanced tumors. This paper reports on the results of our prospective study of limb and pelvic SFP. Thirty-seven patients were treated with SFP. No postoperative deaths occurred. Locoregional and systemic toxicity were observed after 22 and 31 treatments, respectively; complete and partial response after 3 (6%) and 24 (51%) SFPs, respectively. The pharmacokinetic study showed that pelvic SFP was associated with a leakage rate higher than femoral SFP (38% vs 28%). In conclusion, SFP is a feasible procedure. Toxicity and tumor response rates strictly depend upon drug leakage control.

Original languageEnglish
Pages (from-to)44-47
Number of pages4
JournalJournal of Chemotherapy
Issue numberSUPPL. 5
Publication statusPublished - Nov 2004


  • Solid tumors
  • Stop-flow perfusion

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)


Dive into the research topics of 'Hypoxic antiblastic stop-flow perfusion: Clinical outcome and pharmacokinetic findings'. Together they form a unique fingerprint.

Cite this